Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

LA JOLLA, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 20, 2016 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada

LA JOLLA, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 30, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

LA JOLLA, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 27, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China

LA JOLLA, Calif., March 27, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 23, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia

LA JOLLA, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 22, 2016 06:08 ET | Source: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis

LA JOLLA, Calif., March 22, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 07, 2016 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

LA JOLLA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 06, 2016 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas

LA JOLLA, Calif., March 06, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
February 22, 2016 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada

LA JOLLA, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 11, 2016 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas

LA JOLLA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...